GT Biopharma Reports Full Year 2025 Financial Results GT Biopharma (NASDAQ: GTBP) reported full year 2025 results and operational updates on March 2, 2026. The company had $7M cash as of Dec 31, 2025 and an unaudited proforma cash balance of $9M as of Jan 31, 2026, anticipated to fund operations through Q4 2026.GTBP is enrolling a Phase 1 dose‑escalation trial of GTB-3650 and plans to initiate a Phase 1 basket trial of GTB-5550 mid‑2026; next pipeline update expected in Q3 2026.

#GTBP GT Biopharma Reports Full Year 2025 Financial Results

www.stocktitan.net/news/GTBP/gt-biopharma-r...

GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers GT Biopharma (NASDAQ: GTBP) submitted an IND for GTB-5550 to the FDA in December 2025 for a B7-H3-targeted TriKE designed to engage NK cells against B7-H3 expressing solid tumors. The company plans a Phase 1 basket trial in 2026 with a Phase 1a dose escalation cash balance of ~$7 million as of Dec 31, 2025, anticipated to extend runway into Q3 2026.

#GTBP GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers

www.stocktitan.net/news/GTBP/gt-biopharma-a...

GT Biopharma ( #NASDAQ: #GTBP ) explains why the company is expanding into solid tumors, how its NK engager technology targets B7H3, & what milestones investors should watch as the company advances toward clinical data in 2026.

Learn more: www.youtube.com/watch?v=I7-V...

Solid tumors are one of the toughest challenges in cancer care.

Watch GT Biopharma ( #NASDAQ: #GTBP ) CEO Michael Breen break down its NK engager technology and what’s ahead in 2026.

🎬 Watch now: youtu.be/I7-Vd8PO8L0?...

GT Biopharma ( #NASDAQ: #GTBP ) is advancing its TriKE® platform—built with science invented by Prof. Miller, a leading NK-cell expert with 30 years in the field.

Watch the interview for the latest updates: youtu.be/jduKYNKHMIY?...

#GTBP GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials

www.stocktitan.net/news/GTBP/gt-biopharma-i...

GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update Phase 1 trial evaluating GTB-3650 TriKE ® for relapsed or refractory (r/r) CD33 expressing hematologic malignancies continues to actively enroll with the next update anticipated in Q1 2026 GTB-5550 TriKE ® IND submission for B7H3-expressing solid tumors expected in late December 2025 or January

#GTBP GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/GTBP/gt-biopharma-r...

GT Biopharma ( #NASDAQ: #GTBP ) is advancing its next-gen TriKE® immunotherapy.

Watch the full interview with CEO Michael Breen to learn how GTBP is pushing the frontiers of cancer care.

Only on #StocksToWatch: youtu.be/jduKYNKHMIY?...

Cancer treatments haven’t changed much in 80 years: chemo, radiation, or surgery.

GT Biopharma ( #NASDAQ: #GTBP ) is taking a more humane approach with TriKE® technology, empowering the immune system to destroy cancer cells.

🎥 Watch: youtu.be/he9i0aJQ2JM?...

GT Biopharma ( #NASDAQ: #GTBP ) redefines cancer treatment: replacing cutting, burning, & poisoning with precision and the body’s own immune power.

CEO Breen & Dr. J. Miller discuss TriKE® tech, clinical progress, and what’s next in immunotherapy.

🎬 Watch: youtu.be/he9i0aJQ2JM?...

GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies GT Biopharma (NASDAQ: GTBP) reported that the formal safety review of Cohort 3 (5 µg/kg/day) in the Phase 1 GTB-3650 trial completed with no safety or tolerability issues, enabling advancement to Cohort 4 (10 µg/kg/day). Six patients have been treated across Cohorts 1–3. Cohort 4 dosing is expected to begin in the coming weeks and is considered more reflective of a potential efficacy threshold based on positive trends in multiple immunologic biomarkers and absence of dose-limiting toxicities. The protocol allows escalation to Cohorts 5–7 (25, 50, 100 µg/kg/day) if needed. The trial plans up to ~14 patients and will assess safety, PK/PD, NK cell expansion, and clinical activity. Next update expected Q1 2026.

#GTBP GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies

www.stocktitan.net/news/GTBP/gt-biopharma-p...

GT Biopharma ( #NASDAQ: #GTBP ) is advancing its TriKE® nanobody platform — designed to supercharge the body’s natural killer (NK) cells to seek out & destroy cancer.

🎥 Learn how this immune-based approach is changing cancer treatment: youtu.be/Z9tNa4JTELw?...

🚀 GT Biopharma ( #NASDAQ: #GTBP ) is transforming cancer treatment with its TriKE® technology, using NK cells to precisely target & destroy cancer.

Learn the updates on trials, FDA plans, and next-gen nanobody advances, in this interview: youtu.be/he9i0aJQ2JM?...

GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies GT Biopharma (NASDAQ: GTBP) said Phase 1 enrollment for GTB-3650 in r/r CD33‑expressing hematologic malignancies is progressing on schedule.Both patients in Cohort 3 have begun treatment with no dose‑limiting toxicities or tolerability concerns observed to date. The first Cohort 3 patient showed immune activation biomarkers consistent with activity seen in Cohorts 1–2. If Cohort 3 completes without new safety findings, dosing will escalate; Cohort 4 initiation is planned by year‑end 2025 with additional data updates anticipated in Q1 2026. The protocol allows up to ~14 patients across seven cohorts with doses from 1.25 μg/kg/day to 100 μg/kg/day, dosed in two‑week on/off cycles for up to four months.

#GTBP GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies

www.stocktitan.net/news/GTBP/gt-biopharma-p...

GT Biopharma ( #NASDAQ: #GTBP ) is advancing cancer treatment with its TriKE® platform, activating natural killer cells to fight cancer. CEO Breen shares insights on clinical progress, expansion plans, & the future of immunotherapy.

Full video interview: youtu.be/Z9tNa4JTELw?...

GT Biopharma Reports Second Quarter 2025 Financial Results GT Biopharma (NASDAQ: GTBP) has reported its Q2 2025 financial results and provided clinical updates. The company's GTB-3650 TriKE® Phase 1 trial has successfully completed Cohorts 1 and 2, advancing to Cohort 3 with the fifth patient now receiving treatment. The trial is evaluating GTB-3650 in patients with CD33 expressing hematologic malignancies.Financial highlights include cash position of $5.3 million as of June 30, 2025, expected to fund operations into Q1 2026. The company reported reduced quarterly losses with a net loss of $1.4 million, down from $3.7 million in Q2 2024, driven by significant reductions in R&D expenses to $400,000 (down from $1.8M) and SG&A expenses to $1.1 million (down from $2.0M).Additionally, GT Biopharma plans to submit an IND application for GTB-5550 TriKE® in Q4 2025 for the treatment of B7H3 positive solid tumors.

#GTBP GT Biopharma Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/GTBP/gt-biopharma-r...

GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2 GT Biopharma (NASDAQ: GTBP) has advanced to Cohort 3 in its Phase 1 clinical trial of GTB-3650, following successful safety reviews of Cohorts 1 and 2. GTB-3650, a second-generation TriKE® natural killer cell engager, is being evaluated for treating relapsed/refractory CD33-expressing hematologic malignancies.The trial's first four patients have shown encouraging early results, demonstrating GTB-3650's ability to activate and expand NK cells, with multiple blood biomarker assays indicating heightened immune activity. The study plans to enroll up to 14 patients across seven cohorts, with dosing in two-week cycles for up to four months. Initial Phase 1 results are expected later in 2025.

#GTBP GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2

www.stocktitan.net/news/GTBP/gt-biopharma-a...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with declining money flow, Mon Jul 7th - #UFPT #TVGN #GTBP #FNKO #CCSI #AFCG #ZIM #PL #NGL #LVWR #WTF - More: crystalequityresearch.com/SmCpStr/ - #smallcap

GT Biopharma Phase 1 Trial Reveals Early Success: Cancer Drug Shows Safety and Immune Activation Early trial data shows GTB-3650 safety confirmed and immune activation signals detected. Phase 1 advances to second cohort for blood cancer treatment. See full results.

#GTBP GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals

www.stocktitan.net/news/GTBP/gt-biopharma-a...

GT Biopharma's Financial Maneuver: $0.7M Cash Influx Comes With 604K New Warrants GTBP secures immediate capital by reducing warrant exercise price from $4.35 to $2.27, while issuing new warrants at $2.02 with extended terms.

#GTBP GT Biopharma Announces Exercise of Warrants

www.stocktitan.net/news/GTBP/gt-biopharma-a...

GT Biopharma Pulls Back S-1 Filing: What Does This Mean for Their Financing Strategy? GT Biopharma has withdrawn its December 2023 S-1 registration filing before SEC approval. The TriKE® platform developer confirms no securities were sold.

#GTBP GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement

www.stocktitan.net/news/GTBP/gt-biopharma-a...

GT Biopharma Initiates Phase 1 Trial of Advanced TriKE Therapy for Blood Cancers GT Biopharma begins dosing in Phase 1 trial of GTB-3650, its innovative second-generation TriKE therapy targeting CD33-expressing hematologic malignancies. Initial data due 2025.

#GTBP GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies

www.stocktitan.net/news/GTBP/gt-biopharma-a...

#GTBP GT Biopharma Reports Third Quarter 2024 Financial Results

www.stocktitan.net/news/GTBP/gt-biopharma-r...